Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?

JOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley).

Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts